AN2 Therapeutics (ANTX) Research & Development (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Research & Development for 6 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 12.31% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $23.8 million (down 28.94% YoY), while the FY2025 annual figure was $24.8 million, down 38.82% from the prior year.
• Research & Development slipped to $6.7 million in Q1 2026 per ANTX's latest filing, from $6.9 million in the prior quarter.
• Across five years, Research & Development topped out at $14.9 million in Q4 2023 and bottomed at $3.2 million in Q2 2025.
• Historically, Research & Development has averaged $9.1 million across 5 years, with a median of $7.7 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development surged 241.6% — and 2025, when it plunged 73.66%.
• AN2 Therapeutics' Research & Development stood at $8.8 million in 2022, then surged by 70.46% to $14.9 million in 2023, then tumbled by 63.82% to $5.4 million in 2024, then rose by 27.46% to $6.9 million in 2025, then slipped by 1.98% to $6.7 million in 2026.
• Business Quant data shows ANTX's Research & Development at $6.7 million in Q1 2026, $6.9 million in Q4 2025, and $7.0 million in Q3 2025.